On or about December 3, 2020, Silverback Therapeutics common stock began trading on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "SBTX." Pursuant to its IPO, Silverback Therapeutics issued 11.5 million shares of common stock priced at $21.00 per share. Securities and Exchange Commission ("SEC") in connection with its IPO, which, after several amendments, was declared effective by the SEC on December 3, 2020. On November 10, 2020, Silverback Therapeutics filed a registration statement on Form S-1 with the U.S. Lead plaintiff motions for the Silverback Therapeutics class action lawsuit must be filed with the court no later than next Tuesday, January 4, 2022.ĬASE ALLEGATIONS: Silverback Therapeutics' lead product candidate is SBT6050, which is in a Phase 1/1b clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at. Silverback Therapeutics raised $78.5 million in a Series B funding round, the Seattle biotech announced Wednesday.If you wish to serve as lead plaintiff of the Silverback Therapeutics class action lawsuit, please provide your information by clicking here. Silverback Therapeutics raises nearly $80M in Series B shares were down 23% to $12.49 Thursday after the company reported interim clinical results from a Phase 1/1b clinical study of … Silverback Therapeutics Shares Drop 23% After Results for … Using our ImmunoTAC TM platform, we believe it’s possible to develop systemically delivered, tissue-targeted therapeutics for the treatment of chronic viral … Shareholders accuse Seattle health startup of ‘misleading …īiopharmaceutical startup Silverback Therapeutics was sued 11 months after going public, with accusations it had overstated the efficacy of … Salaries, reviews, and more – all posted by employees working at … See what employees say it’s like to work at Silverback Therapeutics. Working at Silverback Therapeutics – Glassdoor Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce Silverback Therapeutics Axes Lead Immuno-Oncology … Silverback Therapeutics is halting its clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring … Silverback Halts Oncology Programs, Lays Off 27% Of Staff Silverback Therapeutics became the latest biotech to undertake a “strategic realignment” Thursday, revealing it would drop its two lead … Silverback falls on hard times, axing lead I/O candidates and laying off more than a fourth of staff Silverback falls on hard times, axing lead I/O candidates and … With more than 30 layoffs tallied by Fierce Biotech, the overpopulated industry is being forced to cut down. Layoff surge hits 3 more biotech companies Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its … Recent News and Discussions About Silverback Therapeutics Layoffs Silverback Therapeutics shuts down oncology program, plans … The Seattle-based company is shuttering its oncology programs after reporting poor clinical results for its lead compound for solid tumors. On Thursday, Silverback Therapeutics announced plans to lay off 27% of its workforce.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |